Next generation patient-derived prostate cancer xenograft models

There is a critical need for more effective therapeutic approaches for prostate cancer. Research in this area, however, has been seriously hampered by a lack of clinically relevant, experimental in vivo models of the disease. This review particularly focuses on the development of prostate cancer xen...

Full description

Bibliographic Details
Main Authors:	Lin, Dong, Xue, Hui, Wang, Yuwei, Wu, Rebecca, Watahiki, Akira, Dong, Xin, Cheng, Hongwei, Wyatt, Alexander W, Collins, Colin C, Gout, Peter W, Wang, Yuzhuo
Format:	Online
Language:	English
Published:	Medknow Publications & Media Pvt Ltd 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023366/

id	pubmed-4023366
recordtype	oai_dc
spelling	pubmed-40233662014-05-22 Next generation patient-derived prostate cancer xenograft models Lin, Dong Xue, Hui Wang, Yuwei Wu, Rebecca Watahiki, Akira Dong, Xin Cheng, Hongwei Wyatt, Alexander W Collins, Colin C Gout, Peter W Wang, Yuzhuo Invited Research Highlight There is a critical need for more effective therapeutic approaches for prostate cancer. Research in this area, however, has been seriously hampered by a lack of clinically relevant, experimental in vivo models of the disease. This review particularly focuses on the development of prostate cancer xenograft models based on subrenal capsule grafting of patients’ tumor tissue into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. This technique allows successful development of transplantable, patient-derived cancer tissue xenograft lines not only from aggressive metastatic, but also from localized prostate cancer tissues. The xenografts have been found to retain key biological properties of the original malignancies, including histopathological and molecular characteristics, tumor heterogeneity, response to androgen ablation and metastatic ability. As such, they are highly clinically relevant and provide valuable tools for studies of prostate cancer progression at cellular and molecular levels, drug screening for personalized cancer therapy and preclinical drug efficacy testing; especially when a panel of models is used to cover a broader spectrum of the disease. These xenograft models could therefore be viewed as next-generation models of prostate cancer. Medknow Publications & Media Pvt Ltd 2014 2014-02-28 /pmc/articles/PMC4023366/ /pubmed/24589467 http://dx.doi.org/10.4103/1008-682X.125394 Text en Copyright: © Asian Journal of Andrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Lin, Dong Xue, Hui Wang, Yuwei Wu, Rebecca Watahiki, Akira Dong, Xin Cheng, Hongwei Wyatt, Alexander W Collins, Colin C Gout, Peter W Wang, Yuzhuo
spellingShingle	Lin, Dong Xue, Hui Wang, Yuwei Wu, Rebecca Watahiki, Akira Dong, Xin Cheng, Hongwei Wyatt, Alexander W Collins, Colin C Gout, Peter W Wang, Yuzhuo Next generation patient-derived prostate cancer xenograft models
author_facet	Lin, Dong Xue, Hui Wang, Yuwei Wu, Rebecca Watahiki, Akira Dong, Xin Cheng, Hongwei Wyatt, Alexander W Collins, Colin C Gout, Peter W Wang, Yuzhuo
author_sort	Lin, Dong
title	Next generation patient-derived prostate cancer xenograft models
title_short	Next generation patient-derived prostate cancer xenograft models
title_full	Next generation patient-derived prostate cancer xenograft models
title_fullStr	Next generation patient-derived prostate cancer xenograft models
title_full_unstemmed	Next generation patient-derived prostate cancer xenograft models
title_sort	next generation patient-derived prostate cancer xenograft models
description	There is a critical need for more effective therapeutic approaches for prostate cancer. Research in this area, however, has been seriously hampered by a lack of clinically relevant, experimental in vivo models of the disease. This review particularly focuses on the development of prostate cancer xenograft models based on subrenal capsule grafting of patients’ tumor tissue into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. This technique allows successful development of transplantable, patient-derived cancer tissue xenograft lines not only from aggressive metastatic, but also from localized prostate cancer tissues. The xenografts have been found to retain key biological properties of the original malignancies, including histopathological and molecular characteristics, tumor heterogeneity, response to androgen ablation and metastatic ability. As such, they are highly clinically relevant and provide valuable tools for studies of prostate cancer progression at cellular and molecular levels, drug screening for personalized cancer therapy and preclinical drug efficacy testing; especially when a panel of models is used to cover a broader spectrum of the disease. These xenograft models could therefore be viewed as next-generation models of prostate cancer.
publisher	Medknow Publications & Media Pvt Ltd
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023366/
_version_	1612089984835125248

Next generation patient-derived prostate cancer xenograft models

Similar Items